跳至主要内容
临床试验/NCT00846911
NCT00846911已完成不适用

AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis

Bayer0 个研究点目标入组 2,672 人开始时间: 2008年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
2,672
主要终点
Time until improvement of acute exacerbation

研究概览

简要总结

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.

This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
35 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.

排除标准

  • Exclusion criteria must be read in conjunction with the local product information.

研究组 & 干预措施

Group 1

干预措施: Moxifloxacin (Avelox, BAY12-8039) (Drug)

结局指标

主要结局

Time until improvement of acute exacerbation

时间窗: End of study

次要结局

  • Time until cure of acute exacerbation(End of study)
  • Severity of AECB according to Antonisen criteria(Baseline)
  • Impact of AECB on daily life activities(Baseline)
  • Safety of Avelox under daily life treatment conditions(Throughout treatment)

研究者

发起方
Bayer
申办方类型
Industry

相似试验